Consumer Electronics company Symphony announced Q2FY26 results Revenue from Operations: Rs 155 crore compared to Rs 259 crore during Q2FY25, change -40%. EBITDA: Rs 27 crore compared to Rs 72 crore during Q2FY25, change -63%. EBITDA Margin: 17.3% for Q2FY26. PAT: Rs 28 crore compared to Rs 67 crore during Q2FY25, change -58%. Nrupesh Shah, Managing Director (Corporate Affairs), Symphony, said: Symphony Limited today reported its financial results for the quarter ended September 2025. The Company recorded a year-on-year standalone revenue decline of 40%, attributable to an inventory overhang in the General Trade (GT) channel for air coolers. Amid this temporary overhang, Symphony’s round-the-year product portfolio – including large space venti cooling, tower fans, kitchen cooling fans, water heaters – recorded a respectable growth, albeit on a low base. The EBITDA margin experienced pressure, reflecting softness in gross margins arising from shifts in product mix and operating deleverage. Symphony reinforced its commitment to sustained growth and product innovation by launching multiple new SKUs in both air coolers and water heaters. The Air Force range of air coolers was expanded from three to seven SKUs, bringing the total number of new air cooler SKUs introduced this quarter to nine. The water heater portfolio was also strengthened with the addition of six new storage SKUs and two instant variants. In October 2025, the Company achieved an additional recovery of Rs 4 crore from Pathways, bringing the total yearto-date recovery of Rs 8.5 crore. This recovery is against Rs 50.2 crore written off during FY25. GSK, China, sustained its growth trajectory and is progressing towards debt-free status, supported by: IPR monetization totaling approximately Rs 45 crore, including receipts of Rs 22 crore year to date, with the balance expected in the December 2025 quarter. further supported by internal cash generation. IMPCO, Mexico reported a steady performance during the non-seasonal air cooler quarter. The Company scaled up its washing machine distribution network through new retail partnerships across the country. Climate Holdings, Australia (formerly Symphony AU) registered its third consecutive quarter of year-on-year growth. Transformation initiatives including asset-light operations, product and market expansion, accelerated sales, and cost optimization continue to drive business momentum. Result PDF
Consumer Electronics company Symphony announced Q1FY26 results Revenue from Operations: Rs 251 crore compared to Rs 393 crore during Q1FY25, change -36%. EBITDA: Rs 26 crore compared to Rs 88 crore during Q1FY25, change -71%. EBITDA Margin: 10.2% for Q1FY26. PAT: Rs 42 crore compared to Rs 88 crore during Q1FY25, change -52%. Nrupesh Shah, Managing Director (Corporate Affairs), Symphony, said: Symphony Limited today announced its financial results for the quarter ending June 2025, reporting a 39% YoY decline in standalone revenue. This is primarily attributed to pronounced seasonal headwinds, further accentuated by a high base of the June 2024 quarter. Symphony delivered its second-highest June quarter (summer-season) standalone revenue on record and surpassed earlier second-best summer season, despite a shortened and rain-impacted summer-25, coupled with the early onset of monsoon. Standalone EBITDA margin declined by 11.7%, primarily due to product mix and YoY reduced operating leverage. GSK China continued its robust growth momentum, making strides towards becoming debt-free. During FY26 yearto-date, GSK China repaid Rs 27.9 crore towards its inter-company loan to Symphony India, reducing outstanding loan to Rs 26.1 crore from a peak of Rs 59.8 crore in May 2024. The trajectory is bolstered by intellectual property rights monetization and internal cash generation. IMPCO Mexico experienced subdued performance attributed to a milder summer, which moderated EBITDA margins due to YoY lower operating leverage. Symphony AU Australia posted its second consecutive quarter of year-on-year growth, driven by ongoing business transformation initiatives. Key levers fueling this momentum include an asset-light operating model, strategic product and market expansion, accelerated sales, and cost optimization. GSK China has successfully transferred technology know-how and nine intellectual property rights (IPRs) to IMPCO Mexico. The total transaction is valued at ~ Rs 44 crore, with the first tranche, amounting to around Rs 22 crore, already completed. The remaining balance is scheduled for completion in the September 2025 quarter. This move not only accelerates IMPCO Mexico’s product-led growth but also enhances prospects for IMPCO’s divestment / monetization. GSK China continues to retain a strong portfolio of products and IPRs, ensuring sustained innovation and future growth. Result PDF
Conference Call with Symphony Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.